ArticleThe Journal of allergy and clinical immunology2022

The arrival of SARS-CoV-2-neutralizing antibodies in a currently available commercial immunoglobulin.

Aaron L Miller et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.